Cryoport logo

CryoportNASDAQ: CYRX

Profile

Country:

United States

IPO:

22 August 2005

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$346.38 M
-91%vs. 3y high
37%vs. sector
-vs. 3y high
-vs. sector
-85%vs. 3y high
25%vs. sector
-91%vs. 3y high
54%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:05:52 GMT
$7.01+$0.50(+7.68%)

Dividend

No data over the past 3 years
$57.60 M$58.04 M
$57.60 M-$77.99 M

Analysts recommendations

Institutional Ownership

CYRX Latest News

Cryoport and Gulf Coast Regional Blood Center Launch Strategic Alliance to Enhance Cellular Therapy Services
prnewswire.com22 October 2024 Sentiment: POSITIVE

Partnership Coincides with the Grand Opening of Cryoport's State-Of-The-Art IntegriCell ™  Houston Facility NASHVILLE, Tenn. and HOUSTON , Oct. 22, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and Gulf Coast Regional Blood Center ("GCRBC"), a non-profit community blood center serving more than 26 counties throughout the state of Texas, today announced a strategic alliance to enhance the availability of high-quality, manufacture-ready cryopreserved allogeneic leukopaks for cellular therapy research, development, and treatment.

TMRW Life Sciences and Cryoport Systems Form Strategic Partnership to Elevate Standards for Frozen Egg, Embryo, and Sperm Offsite Storage and Biologistics
prnewswire.com21 October 2024 Sentiment: POSITIVE

Two ISO-Certified Industry Leaders Collaborate to Provide Fertility Clinics with Complete, Trusted Solutions for Secure IVF Specimen Management and Transport NASHVILLE, Tenn.  and NEW YORK , Oct. 21, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and TMRW Life Sciences ("TMRW"), a fertility technology company offering the highest standard of care in offsite storage for frozen eggs, embryos and sperm in the U.S. with the only FDA-cleared automated specimen management and storage platform, today announced a strategic partnership to provide fertility clinics with complete solutions for secure specimen management and transport.

VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies
prnewswire.com15 October 2024 Sentiment: POSITIVE

Partnership Will Enhance Support for Biopharmaceutical Companies in Developing Cell and Gene Therapies and mRNA-Based Treatments NASHVILLE, Tenn. and CONROE, Texas , Oct. 15, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and VGXI, Inc., (VXGI) a subsidiary of GeneOne Life Science Inc. ("GeneOne" KOSPI: 011000) today announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies and mRNA-based treatments.

SK pharmteco and Cryoport Partner for Cell and Gene Therapy Logistics and BioServices
prnewswire.com25 September 2024 Sentiment: POSITIVE

NASHVILLE, Tenn. and RANCHO CORDOVA, Calif.

The Schall Law Firm Opens Investigation Into Cryoport Inc And Encourages Shareholders To Reach Out
accesswire.com15 August 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Begins Investigation Into Claims Against Cryoport Inc And Encourages Its Shareholders To Reach Out
accesswire.com12 August 2024 Sentiment: NEGATIVE

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Initiates Investigation Into Claims Against Cryoport Inc And Urges Its Shareholders To Contact
accesswire.com09 August 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Begins Probe Into Allegations Against Cryoport Inc And Encourages Its Shareholders To Reach Out
accesswire.com08 August 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Initiates Investigation Into Claims Against Cryoport Inc And Urges Its Shareholders To Get In Touch
accesswire.com07 August 2024 Sentiment: NEGATIVE

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CryoPort, Inc. (CYRX) Reports Q2 Loss, Lags Revenue Estimates
zacks.com06 August 2024 Sentiment: NEUTRAL

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.42 per share a year ago.

What type of business is Cryoport?

CryoPort Inc is a provider of temperature-controlled supply chain solutions for the life sciences industry, offering a unique and evolving platform of critical products and solutions, including advanced packaging, informatics, specialized logistics services, biostorage services, and cryogenic equipment for the biological sciences. The company provides global solutions for the biopharmaceutical, animal health, and human reproductive medicine markets. Its main focus is on meeting the critical needs of the temperature-controlled supply chain in the biopharmaceutical space with an emphasis on servicing the rapidly growing cell and gene therapy market. Cryoport, Inc. was founded in 1999, and the company is headquartered in Brentwood, Tennessee.

What sector is Cryoport in?

Cryoport is in the Industrials sector

What industry is Cryoport in?

Cryoport is in the Integrated Freight & Logistics industry

What country is Cryoport from?

Cryoport is headquartered in United States

When did Cryoport go public?

Cryoport initial public offering (IPO) was on 22 August 2005

What is Cryoport website?

https://www.cryoportinc.com

Is Cryoport in the S&P 500?

No, Cryoport is not included in the S&P 500 index

Is Cryoport in the NASDAQ 100?

No, Cryoport is not included in the NASDAQ 100 index

Is Cryoport in the Dow Jones?

No, Cryoport is not included in the Dow Jones index

When was Cryoport the previous earnings report?

No data

When does Cryoport earnings report?

The next expected earnings date for Cryoport is 08 November 2024